GlassScriptPhysician profile
Terry Andrew Colotta
NPI 1659374296
$5,897.03
in general payments reported to CMS, 2019-2025
41 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $805 · 2021: $990 · 2022: $884 · 2023: $857 · 2024: $1,005 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,774 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,774.35 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,455.77 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $543.16 | 2019-2025 | Evenity, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $366.97 | 2019-2022 | |
| Allergan, INC. | $324.31 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $261.75 | 2020-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $244.96 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $242.49 | 2022-2025 | Caplyta |
| Mylan Specialty L.P. | $230.69 | 2020-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $206.05 | 2019-2024 | Verquvo, Gardasil 9, Proquad |
| Pfizer INC. | $205.26 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $189.14 | 2020-2025 | Rexulti, Jynarque, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.83 | 2019-2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Lilly USA, LLC | $122.06 | 2020-2024 | Jardiance, Mounjaro |
| Novo Nordisk INC | $114.36 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Colotta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.